{
  "transcript_summary": "Johnson & Johnson reported strong Q3 2025 results with 5.4% operational sales growth, driven by its Innovative Medicine and MedTech businesses, and announced the planned separation of its Orthopaedics business to focus on higher-growth areas.",
  "claims": [
    {
      "quote_end_char": 3175,
      "quote_start_char": 3087,
      "comparison_period": "Q3 2024",
      "claim_id": "claim_001",
      "metric_type": "revenue",
      "claimed_value_raw": "5.4%",
      "claim_type": "yoy_growth",
      "scale": null,
      "claimed_value": 5.4,
      "metric_context": "Total",
      "unit": "percent",
      "speaker_role": "ceo",
      "period": "Q3 2025",
      "quote_text": "In the third quarter, we delivered operational sales growth of 5.4% across our business.",
      "confidence": 1,
      "qualifiers": [
        "operational sales growth"
      ],
      "is_approximate": false,
      "gaap_classification": "non_gaap",
      "speaker": "Joaquin Duato"
    },
    {
      "claimed_value_raw": "5.3%",
      "claim_type": "yoy_growth",
      "scale": null,
      "unit": "percent",
      "speaker_role": "ceo",
      "claimed_value": 5.3,
      "metric_context": "Innovative Medicine",
      "quote_end_char": 3309,
      "comparison_period": "Q3 2024",
      "quote_start_char": 3176,
      "metric_type": "revenue",
      "claim_id": "claim_002",
      "qualifiers": [
        "operational sales growth"
      ],
      "gaap_classification": "non_gaap",
      "is_approximate": false,
      "speaker": "Joaquin Duato",
      "period": "Q3 2025",
      "quote_text": "In Innovative Medicine, we reported 5.3% operational sales growth and a second consecutive quarter of sales of more than $15 billion.",
      "confidence": 1
    },
    {
      "confidence": 1,
      "quote_text": "remarkable growth of 40% in TREMFYA.",
      "period": "Q3 2025",
      "speaker": "Joaquin Duato",
      "gaap_classification": "non_gaap",
      "is_approximate": false,
      "qualifiers": [
        "remarkable growth"
      ],
      "metric_type": "revenue",
      "claim_id": "claim_004",
      "quote_start_char": 3717,
      "comparison_period": "Q3 2024",
      "quote_end_char": 3753,
      "speaker_role": "ceo",
      "unit": "percent",
      "metric_context": "TREMFYA",
      "claimed_value": 40,
      "scale": null,
      "claim_type": "yoy_growth",
      "claimed_value_raw": "40%"
    },
    {
      "unit": "percent",
      "speaker_role": "ceo",
      "claimed_value": 5.6,
      "metric_context": "MedTech",
      "scale": null,
      "claimed_value_raw": "5.6%",
      "claim_type": "yoy_growth",
      "metric_type": "revenue",
      "claim_id": "claim_005",
      "comparison_period": "Q3 2024",
      "quote_start_char": 3754,
      "quote_end_char": 3871,
      "speaker": "Joaquin Duato",
      "gaap_classification": "non_gaap",
      "is_approximate": false,
      "qualifiers": [
        "operational sales growth"
      ],
      "confidence": 1,
      "quote_text": "In MedTech, operational sales growth was even stronger, accelerating to 5.6% with improvements across all businesses.",
      "period": "Q3 2025"
    },
    {
      "comparison_period": "Q3 2024",
      "quote_start_char": 4583,
      "metric_type": "revenue",
      "claim_id": "claim_006",
      "quote_end_char": 4643,
      "unit": "percent",
      "speaker_role": "ceo",
      "claimed_value": 20,
      "metric_context": "Oncology",
      "claimed_value_raw": "20%",
      "claim_type": "yoy_growth",
      "scale": null,
      "confidence": 1,
      "period": "Q3 2025",
      "quote_text": "First, Oncology, where Q3 operational sales grew nearly 20%.",
      "gaap_classification": "non_gaap",
      "is_approximate": true,
      "speaker": "Joaquin Duato",
      "qualifiers": [
        "nearly",
        "operational sales grew"
      ]
    },
    {
      "confidence": 1,
      "quote_text": "Q3 operational sales of DARZALEX grew by 20%",
      "period": "Q3 2025",
      "speaker": "Joaquin Duato",
      "is_approximate": false,
      "gaap_classification": "non_gaap",
      "qualifiers": [
        "operational sales grown by"
      ],
      "claim_id": "claim_007",
      "metric_type": "revenue",
      "quote_start_char": 5100,
      "comparison_period": "Q3 2024",
      "quote_end_char": 5144,
      "claimed_value": 20,
      "metric_context": "DARZALEX",
      "unit": "percent",
      "speaker_role": "ceo",
      "scale": null,
      "claimed_value_raw": "20%",
      "claim_type": "yoy_growth"
    },
    {
      "qualifiers": [
        "more than",
        "operational sales growing by"
      ],
      "is_approximate": true,
      "gaap_classification": "non_gaap",
      "speaker": "Joaquin Duato",
      "period": "Q3 2025",
      "quote_text": "With operational sales growing by more than 80% this quarter, we are increasingly confident in Carvicti's $5 billion peak year sales potential.",
      "confidence": 1,
      "claim_type": "yoy_growth",
      "claimed_value_raw": "80%",
      "scale": null,
      "metric_context": "Carvicti",
      "claimed_value": 80,
      "speaker_role": "ceo",
      "unit": "percent",
      "quote_end_char": 5699,
      "quote_start_char": 5556,
      "comparison_period": "Q3 2024",
      "claim_id": "claim_008",
      "metric_type": "revenue"
    },
    {
      "period": "annual peak year",
      "quote_text": "It will also contribute significantly to future growth, with a targeted release platform projected to be another blockbuster treatment with at least $5 billion in annual peak year sales.",
      "confidence": 1,
      "qualifiers": [
        "at least",
        "projected to be another blockbuster"
      ],
      "gaap_classification": "gaap",
      "is_approximate": false,
      "speaker": "Joaquin Duato",
      "quote_end_char": 6350,
      "quote_start_char": 6164,
      "comparison_period": null,
      "metric_type": "revenue",
      "claim_id": "claim_010",
      "claim_type": "guidance",
      "claimed_value_raw": "$5 billion",
      "scale": "billions",
      "speaker_role": "ceo",
      "unit": "dollars",
      "metric_context": "Inlexo",
      "claimed_value": 5
    },
    {
      "quote_end_char": 7056,
      "comparison_period": null,
      "quote_start_char": 6871,
      "metric_type": "revenue",
      "claim_id": "claim_011",
      "claim_type": "guidance",
      "claimed_value_raw": "$5 billion",
      "scale": "billions",
      "speaker_role": "ceo",
      "unit": "dollars",
      "claimed_value": 5,
      "metric_context": "DriverBand plus Las Cruze",
      "period": "big year",
      "quote_text": "The combination of DriverBand plus Las Cruze is another of our $5 billion big year sales assets. Next, I want to talk about immunology, where we have been leaders for twenty-five years.",
      "confidence": 1,
      "qualifiers": [],
      "gaap_classification": "gaap",
      "is_approximate": false,
      "speaker": "Joaquin Duato"
    },
    {
      "claimed_value_raw": "40%",
      "claim_type": "yoy_growth",
      "scale": null,
      "unit": "percent",
      "speaker_role": "ceo",
      "claimed_value": 40,
      "metric_context": "Tremfya",
      "quote_end_char": 7468,
      "quote_start_char": 7276,
      "comparison_period": "Q3 2024",
      "metric_type": "revenue",
      "claim_id": "claim_012",
      "qualifiers": [
        "operational sales growth of"
      ],
      "gaap_classification": "non_gaap",
      "is_approximate": false,
      "speaker": "Joaquin Duato",
      "period": "Q3 2025",
      "quote_text": "Based on this quarter's performance, it looks like it could be both bigger and better, having delivered operational sales growth of 40% driven by new indications in inflammatory bowel disease.",
      "confidence": 1
    },
    {
      "confidence": 1,
      "quote_text": "We are confident Tremfya will become a more than $10 billion asset.",
      "period": "future",
      "speaker": "Joaquin Duato",
      "gaap_classification": "unknown",
      "is_approximate": false,
      "qualifiers": [
        "more than",
        "asset"
      ],
      "metric_type": "other",
      "claim_id": "claim_013",
      "comparison_period": null,
      "quote_start_char": 7815,
      "quote_end_char": 7882,
      "unit": "dollars",
      "speaker_role": "ceo",
      "claimed_value": 10,
      "metric_context": "Tremfya",
      "scale": "billions",
      "claimed_value_raw": "$10 billion",
      "claim_type": "guidance"
    },
    {
      "confidence": 1,
      "quote_text": "Let's now turn to neuroscience, with the Spravato operational sales growing an impressive 61% in Q3.",
      "period": "Q3 2025",
      "speaker": "Joaquin Duato",
      "is_approximate": false,
      "gaap_classification": "non_gaap",
      "qualifiers": [
        "operational sales growing an impressive"
      ],
      "claim_id": "claim_014",
      "metric_type": "revenue",
      "quote_start_char": 8488,
      "comparison_period": "Q3 2024",
      "quote_end_char": 8588,
      "metric_context": "Spravato",
      "claimed_value": 61,
      "speaker_role": "ceo",
      "unit": "percent",
      "scale": null,
      "claimed_value_raw": "61%",
      "claim_type": "yoy_growth"
    },
    {
      "confidence": 1,
      "period": "annually",
      "quote_text": "We project CAPLYTA to reach $5 billion annually.",
      "gaap_classification": "gaap",
      "is_approximate": false,
      "speaker": "Joaquin Duato",
      "qualifiers": [
        "projected to reach"
      ],
      "quote_start_char": 9181,
      "comparison_period": null,
      "metric_type": "revenue",
      "claim_id": "claim_015",
      "quote_end_char": 9229,
      "speaker_role": "ceo",
      "unit": "dollars",
      "metric_context": "CAPLYTA",
      "claimed_value": 5,
      "claimed_value_raw": "$5 billion",
      "claim_type": "guidance",
      "scale": "billions"
    },
    {
      "quote_end_char": 9371,
      "claim_id": "claim_016",
      "metric_type": "revenue",
      "comparison_period": "Q3 2024",
      "quote_start_char": 9230,
      "scale": null,
      "claimed_value_raw": "12%",
      "claim_type": "yoy_growth",
      "claimed_value": 12,
      "metric_context": "Cardiovascular",
      "unit": "percent",
      "speaker_role": "ceo",
      "quote_text": "Now let's turn to MEDTEC, starting with our cardiovascular portfolio. In Q3, cardiovascular operational sales increased by approximately 12%.",
      "period": "Q3 2025",
      "confidence": 1,
      "qualifiers": [
        "approximately",
        "operational sales increased by"
      ],
      "speaker": "Joaquin Duato",
      "is_approximate": true,
      "gaap_classification": "non_gaap"
    },
    {
      "quote_text": "With operational sales growth of over 20%, Shockwave's unique intravascular lithotripsy technology is helping treat more atherosclerotic cardiovascular patients than ever before.",
      "period": "Q3 2025",
      "confidence": 1,
      "qualifiers": [
        "operational sales growth of over"
      ],
      "speaker": "Joaquin Duato",
      "gaap_classification": "non_gaap",
      "is_approximate": false,
      "quote_end_char": 9640,
      "metric_type": "revenue",
      "claim_id": "claim_017",
      "quote_start_char": 9462,
      "comparison_period": "Q3 2024",
      "scale": null,
      "claim_type": "yoy_growth",
      "claimed_value_raw": "20%",
      "speaker_role": "ceo",
      "unit": "percent",
      "metric_context": "Shockwave",
      "claimed_value": 20
    },
    {
      "scale": null,
      "claimed_value_raw": "10%",
      "claim_type": "yoy_growth",
      "metric_context": "Electrophysiology",
      "claimed_value": 10,
      "speaker_role": "ceo",
      "unit": "percent",
      "quote_end_char": 10107,
      "claim_id": "claim_018",
      "metric_type": "revenue",
      "quote_start_char": 10044,
      "comparison_period": "Q3 2024",
      "qualifiers": [
        "close to",
        "operational sales growth"
      ],
      "speaker": "Joaquin Duato",
      "is_approximate": true,
      "gaap_classification": "non_gaap",
      "quote_text": "In Q3, we again delivered close to 10% operational sales growth",
      "period": "Q3 2025",
      "confidence": 1
    },
    {
      "comparison_period": "Q3 2024",
      "quote_start_char": 10295,
      "claim_id": "claim_019",
      "metric_type": "revenue",
      "quote_end_char": 10411,
      "claimed_value": 15,
      "metric_context": "Abiomed",
      "speaker_role": "ceo",
      "unit": "percent",
      "claim_type": "yoy_growth",
      "claimed_value_raw": "15%",
      "scale": null,
      "confidence": 1,
      "period": "Q3 2025",
      "quote_text": "Our Abiomed business also continues to perform strongly, with more than 15% operational sales growth in the quarter.",
      "is_approximate": true,
      "gaap_classification": "non_gaap",
      "speaker": "Joaquin Duato",
      "qualifiers": [
        "more than",
        "operational sales growth"
      ]
    },
    {
      "quote_text": "And in Q3, delivered more than 9% growth in biosurgery and almost 7% in wound closure",
      "period": "Q3 2025",
      "confidence": 1,
      "qualifiers": [
        "more than"
      ],
      "speaker": "Joaquin Duato",
      "gaap_classification": "non_gaap",
      "is_approximate": true,
      "quote_end_char": 11201,
      "metric_type": "revenue",
      "claim_id": "claim_020",
      "comparison_period": "Q3 2024",
      "quote_start_char": 11116,
      "scale": null,
      "claimed_value_raw": "9%",
      "claim_type": "yoy_growth",
      "unit": "percent",
      "speaker_role": "ceo",
      "claimed_value": 9,
      "metric_context": "Biosurgery"
    },
    {
      "quote_end_char": 11431,
      "quote_start_char": 11372,
      "comparison_period": "Q3 2024",
      "metric_type": "revenue",
      "claim_id": "claim_022",
      "claim_type": "yoy_growth",
      "claimed_value_raw": "6%",
      "scale": null,
      "speaker_role": "ceo",
      "unit": "percent",
      "metric_context": "Vision",
      "claimed_value": 6,
      "period": "Q3 2025",
      "quote_text": "And now to vision, where we grew more than 6% last quarter.",
      "confidence": 1,
      "qualifiers": [
        "more than",
        "grew"
      ],
      "gaap_classification": "non_gaap",
      "is_approximate": true,
      "speaker": "Joaquin Duato"
    },
    {
      "metric_type": "revenue",
      "claim_id": "claim_023",
      "quote_start_char": 11432,
      "comparison_period": "Q3 2024",
      "quote_end_char": 11587,
      "speaker_role": "ceo",
      "unit": "percent",
      "claimed_value": 13.8,
      "metric_context": "Surgical Vision",
      "scale": null,
      "claim_type": "yoy_growth",
      "claimed_value_raw": "13.8%",
      "confidence": 1,
      "quote_text": "Our Technis intraocular lenses are the fastest growing in the market where we have launched, fueling our 13.8% operational sales growth in Surgical Vision.",
      "period": "Q3 2025",
      "speaker": "Joaquin Duato",
      "gaap_classification": "non_gaap",
      "is_approximate": false,
      "qualifiers": [
        "operational sales growth"
      ]
    },
    {
      "quote_end_char": 14067,
      "claim_id": "claim_024",
      "metric_type": "revenue",
      "comparison_period": null,
      "quote_start_char": 14018,
      "scale": "billions",
      "claimed_value_raw": "$24 billion",
      "claim_type": "absolute",
      "claimed_value": 24,
      "metric_context": "Total",
      "unit": "dollars",
      "speaker_role": "management",
      "quote_text": "Worldwide sales were $24 billion for the quarter.",
      "period": "Q3 2025",
      "confidence": 1,
      "qualifiers": [],
      "speaker": "Darren Snellgrove",
      "is_approximate": false,
      "gaap_classification": "gaap"
    },
    {
      "qualifiers": [],
      "gaap_classification": "gaap",
      "is_approximate": false,
      "speaker": "Darren Snellgrove",
      "period": "Q3 2025",
      "quote_text": "For the quarter, net earnings were $5.2 billion",
      "confidence": 1,
      "claimed_value_raw": "$5.2 billion",
      "claim_type": "absolute",
      "scale": "billions",
      "unit": "dollars",
      "speaker_role": "management",
      "claimed_value": 5.2,
      "metric_context": "Total",
      "quote_end_char": 14420,
      "comparison_period": null,
      "quote_start_char": 14373,
      "metric_type": "net_income",
      "claim_id": "claim_025"
    },
    {
      "quote_start_char": 14422,
      "comparison_period": null,
      "claim_id": "claim_026",
      "metric_type": "eps_diluted",
      "quote_end_char": 14517,
      "metric_context": "Total",
      "claimed_value": 2.12,
      "unit": "per_share",
      "speaker_role": "management",
      "claim_type": "absolute",
      "claimed_value_raw": "$2.12",
      "scale": null,
      "confidence": 1,
      "period": "Q3 2025",
      "quote_text": "with diluted earnings per share of $2.12 versus diluted earnings per share of $1.11 a year ago.",
      "is_approximate": false,
      "gaap_classification": "gaap",
      "speaker": "Darren Snellgrove",
      "qualifiers": []
    },
    {
      "unit": "dollars",
      "speaker_role": "management",
      "claimed_value": 6.8,
      "metric_context": "Total",
      "claimed_value_raw": "$6.8 billion",
      "claim_type": "absolute",
      "scale": "billions",
      "quote_start_char": 14518,
      "comparison_period": null,
      "metric_type": "net_income",
      "claim_id": "claim_027",
      "quote_end_char": 14681,
      "gaap_classification": "non_gaap",
      "is_approximate": false,
      "speaker": "Darren Snellgrove",
      "qualifiers": [
        "adjusted net earnings"
      ],
      "confidence": 1,
      "period": "Q3 2025",
      "quote_text": "Adjusted net earnings for the quarter were $6.8 billion, with adjusted diluted earnings per share of $2.8, both representing an increase of 15.7% compared to 2024."
    },
    {
      "quote_end_char": 14681,
      "comparison_period": null,
      "quote_start_char": 14518,
      "claim_id": "claim_028",
      "metric_type": "eps_diluted",
      "claimed_value_raw": "$2.8",
      "claim_type": "absolute",
      "scale": null,
      "claimed_value": 2.8,
      "metric_context": "Total",
      "unit": "per_share",
      "speaker_role": "management",
      "period": "Q3 2025",
      "quote_text": "Adjusted net earnings for the quarter were $6.8 billion, with adjusted diluted earnings per share of $2.8, both representing an increase of 15.7% compared to 2024.",
      "confidence": 1,
      "qualifiers": [
        "adjusted diluted earnings per share"
      ],
      "is_approximate": false,
      "gaap_classification": "non_gaap",
      "speaker": "Darren Snellgrove"
    },
    {
      "qualifiers": [
        "achieved sales of"
      ],
      "speaker": "Darren Snellgrove",
      "gaap_classification": "gaap",
      "is_approximate": false,
      "quote_text": "Carvictee achieved sales of $524 million with growth of 81.4%, driven by share gains and site expansion.",
      "period": "Q3 2025",
      "confidence": 1,
      "scale": "millions",
      "claimed_value_raw": "$524 million",
      "claim_type": "absolute",
      "unit": "dollars",
      "speaker_role": "management",
      "claimed_value": 524,
      "metric_context": "Carvictee",
      "quote_end_char": 15868,
      "metric_type": "revenue",
      "claim_id": "claim_030",
      "comparison_period": null,
      "quote_start_char": 15764
    },
    {
      "comparison_period": null,
      "quote_start_char": 16239,
      "metric_type": "revenue",
      "claim_id": "claim_032",
      "quote_end_char": 16372,
      "unit": "dollars",
      "speaker_role": "management",
      "claimed_value": 198,
      "metric_context": "Ribrovan plus Lasclus",
      "claimed_value_raw": "$198 million",
      "claim_type": "absolute",
      "scale": "millions",
      "confidence": 1,
      "period": "Q3 2025",
      "quote_text": "In lung cancer, Ribrovan plus Lasclus delivered sales of $198 million and growth over 100%, driven by continued strong launch uptake.",
      "gaap_classification": "gaap",
      "is_approximate": false,
      "speaker": "Darren Snellgrove",
      "qualifiers": []
    },
    {
      "metric_type": "revenue",
      "claim_id": "claim_033",
      "comparison_period": null,
      "quote_start_char": 17052,
      "quote_end_char": 17249,
      "unit": "dollars",
      "speaker_role": "management",
      "claimed_value": 8.4,
      "metric_context": "MedTech",
      "scale": "billions",
      "claimed_value_raw": "$8.4 billion",
      "claim_type": "absolute",
      "confidence": 1,
      "quote_text": "Worldwide sales of $8.4 billion increased 5.6% with growth of 6.6% in The U.S. and 4.5% outside The U.S., driven by strong performance in our three focus areas: cardiovascular, surgery, and vision.",
      "period": "Q3 2025",
      "speaker": "Darren Snellgrove",
      "gaap_classification": "gaap",
      "is_approximate": false,
      "qualifiers": []
    },
    {
      "qualifiers": [],
      "gaap_classification": "gaap",
      "is_approximate": false,
      "speaker": "Darren Snellgrove",
      "period": "Q3 2025",
      "quote_text": "Orthopedic growth this quarter is gaining momentum and increased to 2.4%.",
      "confidence": 1,
      "claimed_value_raw": "2.4%",
      "claim_type": "yoy_growth",
      "scale": null,
      "unit": "percent",
      "speaker_role": "management",
      "claimed_value": 2.4,
      "metric_context": "Orthopedic",
      "quote_end_char": 18898,
      "comparison_period": "Q3 2024",
      "quote_start_char": 18825,
      "metric_type": "revenue",
      "claim_id": "claim_034"
    },
    {
      "metric_type": "research_and_development",
      "claim_id": "claim_035",
      "quote_start_char": 19909,
      "comparison_period": null,
      "quote_end_char": 20026,
      "unit": "dollars",
      "speaker_role": "management",
      "claimed_value": 3.7,
      "metric_context": "Total",
      "scale": "billions",
      "claimed_value_raw": "$3.7 billion",
      "claim_type": "absolute",
      "confidence": 1,
      "quote_text": "We continued our strong investment in research and development with $3.7 billion or approximately 15% of sales in Q3.",
      "period": "Q3 2025",
      "speaker": "Darren Snellgrove",
      "gaap_classification": "gaap",
      "is_approximate": false,
      "qualifiers": []
    },
    {
      "confidence": 1,
      "period": "nine months of the year 2025",
      "quote_text": "We generated $14 billion in free cash flow through the first nine months of the year.",
      "gaap_classification": "unknown",
      "is_approximate": false,
      "speaker": "Joe Wolk",
      "qualifiers": [
        "generated"
      ],
      "quote_start_char": 23425,
      "comparison_period": null,
      "metric_type": "free_cash_flow",
      "claim_id": "claim_036",
      "quote_end_char": 23510,
      "speaker_role": "cfo",
      "unit": "dollars",
      "metric_context": "Total",
      "claimed_value": 14,
      "claim_type": "absolute",
      "claimed_value_raw": "$14 billion",
      "scale": "billions"
    },
    {
      "gaap_classification": "non_gaap",
      "is_approximate": false,
      "speaker": "Joe Wolk",
      "qualifiers": [
        "midpoint of",
        "operational sales growth"
      ],
      "confidence": 1,
      "period": "FY 2025",
      "quote_text": "We are increasing operational sales guidance for the full year by approximately $300 million, resulting in operational sales growth for the full year in the range of 4.8% to 5.3%, with a midpoint of $93.2 billion or 5.1%.",
      "speaker_role": "cfo",
      "unit": "dollars",
      "metric_context": "Total",
      "claimed_value": 93.2,
      "claim_type": "guidance",
      "claimed_value_raw": "$93.2 billion",
      "scale": "billions",
      "quote_start_char": 26629,
      "comparison_period": null,
      "metric_type": "revenue",
      "claim_id": "claim_037",
      "quote_end_char": 26850
    },
    {
      "confidence": 1,
      "period": "FY 2025",
      "quote_text": "As such, our expected adjusted earnings per share guidance remains $10.85 or 8.7% at the midpoint, with a range of $10.8 to $10.9.",
      "gaap_classification": "non_gaap",
      "is_approximate": false,
      "speaker": "Joe Wolk",
      "qualifiers": [
        "expected adjusted earnings per share guidance remains"
      ],
      "comparison_period": null,
      "quote_start_char": 29181,
      "metric_type": "eps_diluted",
      "claim_id": "claim_038",
      "quote_end_char": 29311,
      "unit": "per_share",
      "speaker_role": "cfo",
      "metric_context": "Total",
      "claimed_value": 10.85,
      "claim_type": "guidance",
      "claimed_value_raw": "$10.85",
      "scale": null
    }
  ],
  "total_claims_found": 38,
  "ticker": "JNJ",
  "year": 2025,
  "quarter": 3,
  "extracted_at": "2026-02-13T17:37:26.997497"
}